Clinical Trials

Find trials

Perform a New Search

Search Results 181-190 of 406 for multiple

Edit search filters

Ixazomib Citrate, Pomalidomide, Dexamethasone, And Stem Cell Transplantation In Treating Patients With Relapsed Or Refractory Multiple Myeloma

Rochester, MN
- See Details
Ixazomib Citrate, Pomalidomide, Dexamethasone, And Stem Cell Transplantation In Treating Patients With Relapsed Or Refractory Multiple Myeloma
- Study type:
  Interventional
  Describes the nature of a clinical study. Types include:
  
  Observational study — observes people and measures outcomes without affecting results.
  
  Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
  
  Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
- Study phase:
  2
  During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.
About this study

This phase II trial studies how well ixazomib citrate, pomalidomide, dexamethasone, and stem cell transplantation works in treating patients with multiple myeloma that has come back or does not respond to treatment. Giving chemotherapy, such as pomalidomide and dexamethasone, before a stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient?s bone marrow for new blood-forming cells (stem cells) to grow. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Giving ixazomib citrate in addition to pomalidomide, dexamethasone, and stem cell transplantation may work better in treating patients with relapsed or refractory multiple myeloma.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, MN

Closed for enrollment
View complete study & contact information

Print study details
Site IRB:
17-003292

NCT ID:
NCT03202628

Sponsor Protocol Number:
MC168A
Bortezomib, Melphalan, And Total-Body Irradiation Before Stem Cell Transplant In Treating Patients With Multiple Myeloma

Rochester, MN
- See Details
Bortezomib, Melphalan, And Total-Body Irradiation Before Stem Cell Transplant In Treating Patients With Multiple Myeloma
- Study type:
  Interventional
  Describes the nature of a clinical study. Types include:
  
  Observational study — observes people and measures outcomes without affecting results.
  
  Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
  
  Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
- Study phase:
  1/2
  During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.
About this study

This phase I/II trial studies the side effects and best dose of bortezomib when given together with melphalan, and total-body irradiation before stem cell transplant and to see how well it works in treating patients with multiple myeloma. Giving chemotherapy and total-body irradiation before a stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. The stem cells that were collected from the patient''s blood or bone marrow are returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy and total-body irradiation.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, MN

Closed for enrollment
View complete study & contact information

Print study details
Site IRB:
12-008546

NCT ID:
NCT01936090

Sponsor Protocol Number:
MC1286

Mayo Clinic Location	Status	Contact
Rochester, MN	Closed for enrollment	View complete study & contact information

Mayo Clinic Location	Status	Contact
Rochester, MN	Closed for enrollment	View complete study & contact information

Dinaciclib, Bortezomib, And Dexamethasone In Treating Patients With Relapsed Multiple Myeloma

Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

See Details

Dinaciclib, Bortezomib, And Dexamethasone In Treating Patients With Relapsed Multiple Myeloma

Study type:
Interventional
Describes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study phase:
1
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

About this study

This phase I trial studies the side effects and best dose of dinaciclib and bortezomib when given together with dexamethasone in treating patients with relapsed multiple myeloma. Dinaciclib and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving dinaciclib and bortezomib together with dexamethasone may kill more cancer cells.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location	Status	Contact
Scottsdale/Phoenix, AZ	Closed for enrollment	View complete study & contact information
Jacksonville, FL	Closed for enrollment
Rochester, MN	Closed for enrollment

Print study details

Site IRB:
11-007230
NCT ID:
NCT01711528
Sponsor Protocol Number:
MC1113

Mayo Clinic Location	Status	Contact
Rochester, MN	Closed for enrollment	View complete study & contact information

Mayo Clinic Location	Status	Contact
Jacksonville, FL	Closed for enrollment	View complete study & contact information

A Study To Evaluate ION251 To Treat Patients With Relapsed/Refractory Multiple Myleoma

Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

See Details

A Study To Evaluate ION251 To Treat Patients With Relapsed/Refractory Multiple Myleoma

Study type:
Interventional
Describes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
Study phase:
1
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

About this study

The purpose of this study is to determine the maximum-tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of ION251 in patients with relapsed/refractory multiple myeloma.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location	Status	Contact
Scottsdale/Phoenix, AZ	Closed for enrollment	View complete study & contact information
Jacksonville, FL	Closed for enrollment
Rochester, MN	Closed for enrollment

Print study details

Site IRB:
20-010126
NCT ID:
NCT04398485
Sponsor Protocol Number:
ION251-CS1

A Study Of TRX319 In Subjects With Primary Or Secondary Progressive Multiple Sclerosis

Rochester, MN
- See Details
A Study Of TRX319 In Subjects With Primary Or Secondary Progressive Multiple Sclerosis
- Study type:
  Interventional
  Describes the nature of a clinical study. Types include:
  
  Observational study — observes people and measures outcomes without affecting results.
  
  Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
  
  Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
- Study phase:
  1
  During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.
About this study

Patients with progressive forms of multiple sclerosis (MS) have limited
therapeutic options and require new, effective treatments. Ocrelizumab, an
anti-CD20 monoclonal antibody (mAb) that depletes B cells, is currently
the only approved drug in the United States for primary progressive MS
(PPMS). Although ocrelizumab has been shown to deplete B cells in the
cerebrospinal fluid (CSF), a lack of reduction of oligoclonal bands (OCBs)
or immunoglobulin G (IgG) index indicates incomplete depletion and
continued persistence of pathogenic B cells in the brain (Yu 2013), which
could limit its potential efficacy. In addition to anti-CD20 antibodies, only
siponimod, a small molecule drug targeting sphingosine 1 phosphate (S1P)
receptor, and cladribine, a purine nucleoside analogue, are currently
approved for secondary progressive MS (SPMS). None of these medications
fully halt or reverse disease progression. Chimeric antigen receptor
(CAR)-T cells targeting CD19 have a wider spectrum of B-cell depletion
than anti-CD20 mAbs and can target central nervous system (CNS)-resident
B cells by crossing the blood-brain-barrier (BBB) (Richter 2024, Dunn 2025,
Seshadri 2024). These autologous CD19 CAR-T cell therapies have recently
shown early signs of efficacy in MS (Dunn 2025) and other autoimmune
conditions, although further studies are needed to confirm their
effectiveness and safety (Haghikia 2024).
TRX319 is a novel allogeneic, off-the-shelf CD19 CAR-Type 1 regulatory
T (Tr1) cell product capable of suppressing pathogenic T-cell and
inflammatory responses (by inhibiting the production of pro-inflammatory
cytokines IL-1, IL-6, and TNF-) in addition to robust CD19 CAR
mediated B-cell depletion. Because TRX319 has anti-inflammatory
properties, TRX319 cells are expected to have an improved safety profile
(due to IL-6 inhibition) compared to current effector CD19 CAR-T cell
therapies that can result in cytokine release syndrome (CRS) and immune
effector cell-associated neurotoxicity syndrome (ICANS). Therefore,
TRX319 may represent a novel treatment option for patients with
progressive forms of MS.

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, MN

Contact us for the latest status
View complete study & contact information

Print study details
Site IRB:
25-013975

Sponsor Protocol Number:
TRX319-01

Mayo Clinic Location	Status	Contact
Rochester, MN	Contact us for the latest status	View complete study & contact information

Pagination Clinical studies

Clinical Trials

Filter Results

Locations

Study status

Gender

Age

Healthy Volunteer

Study phase

Search Results 181-190 of 406 for multiple

Ixazomib Citrate, Pomalidomide, Dexamethasone, And Stem Cell Transplantation In Treating Patients With Relapsed Or Refractory Multiple Myeloma

Bortezomib, Melphalan, And Total-Body Irradiation Before Stem Cell Transplant In Treating Patients With Multiple Myeloma

Dinaciclib, Bortezomib, And Dexamethasone In Treating Patients With Relapsed Multiple Myeloma

Study Evaluating ABT-199 In Subjects With Relapsed Or Refractory Multiple Myeloma

Lenalidomide And Dexamethasone With Or Without Anakinra In Treating Patients With Early Stage Multiple Myeloma

A Study To Evaluate The Safety, Pharmacokinetics, And Efficacy Of Isatuximab In Patients With Multiple Myeloma

Panobinostat And Everolimus In Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, Or Hodgkin Lymphoma

A Study To Evaluate Daratumumab In Treating Transplant-Eligible Participants With Multiple Myeloma

A Study To Evaluate ION251 To Treat Patients With Relapsed/Refractory Multiple Myleoma

A Study Of TRX319 In Subjects With Primary Or Secondary Progressive Multiple Sclerosis

Mayo Clinic Footer

Legal Conditions and Terms

Advertising

Reprint Permissions